SNUBI Research ::   (252 talks satisfying Presenter = ֿ)
All  Seminar  BioEMR  xMutant  SysBiol  MAInfo  J.Club  TopicSem  BookReading    This week    Help

ADD NEW USER

:   ǥ:    /Ű:    ¥:   

2021-08:
12 ֿ Replicating Parkinsons disease genetic analysis with UK Biobank  TopicSem
21 ֿ Utilising large electronic medical record datasets to identify novel drug-gene interactions for commonly used drugs     J.Club

2021-07:
08 ֿ Parkinson disease genetic analysis with UK Biobank  TopicSem
27 ֿ Comparing distribution of variants in PD genes among 1KGP3 populations  SysBiol
28 ֿ Evaluating candidate Parkinson disease genes with UK biobank  BioEMR
28 ֿ Evaluating candidate Parkinson disease genes with UK biobank  BioEMR

2021-06:
03 ֿ Genomic variant analysis and interpretation for Parkinsons disease  TopicSem
03 ֿ Genomic variant analysis and interpretation for Parkinsons disease  TopicSem
08 ֿ Revised association between PGx haplotype frequency and drug use in the UKBB population  SysBiol
16 ֿ Examining polypharmacy in the Korean elderly  BioEMR
19 ֿ Exome-wide evaluation of rare coding variants using electronic health records identifies new gene-phenotype associations     J.Club

2021-04:
14 ֿ Evaluating risk of problems from Beers Criteria medication combinations  BioEMR

2021-03:
23 ֿ Parkinsons disease Genomic Analysis  Seminar

2020-12:
03 ֿ Evaluating PGx molecular phenotype or haplotype frequency association with drug exposure using UK Biobank  TopicSem
03 ֿ Evaluating PGx molecular phenotype or haplotype frequency association with drug exposure using UK Biobank  TopicSem
03 ֿ Refining the clinical definition of clopidogrel adverse events  SysBiol
14 ֿ PhaCT: a novel approach for preemptive PGx testing and medication therapy optimization  BioEMR

2020-11:
02 ֿ Selecting ancestry informative markers and random variants for synthetic association analysis  BioEMR
12 ֿ Evaluating CPIC PGx variant associated ADE risks with UK Biobank  TopicSem
23 ֿ Comparing CPIC star allele phenotype or genotype frequencies between the 1000 Genomes and UKBB population  BioEMR
28 ֿ Population structure and pharmacogenomic risk stratification in the United States     J.Club

2020-10:
10 ֿ Polygenic architecture informs potential vulnerability to drug-induced liver injury     J.Club
12 ֿ Progress in star allele calling for UKBB  BioEMR
22 ֿ Primary care prescription drug use and related actionable drug-gene interactions in the Danish population  SysBiol
26 ֿ Examining the impact of pharmacogenomics testing with UK Biobank and its use for ADR risk comparisons  TopicSem

2020-09:
21 ֿ Applying modified method of candidate SAG extraction  TopicSem
21 ֿ Star allele calling for UKBB  BioEMR

2020-08:
27 ֿ Updates of process and criteria for candidate SAG extraction  TopicSem
31 ֿ Identifying populations likely to benefit from pharmacogenomic testing  SysBiol
31 ֿ Implementation of pharmacogenomics via a research biobank  BioEMR

2020-07:
13 ֿ The implementation of pharmacogenomics for older adults  SysBiol
20 ֿ Properties of the imputed genotype data format BGEN  BioEMR
25 ֿ Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients     J.Club
30 ֿ Frequency of ADR genotypes in UK Biobank  TopicSem

2020-06:
04 ֿ Estimating occurrence of South Koreans with ADR-associated genotypes  TopicSem
15 ֿ Estimating occurrence of adverse drug event risk genotypes with UK Biobank: data exploration  BioEMR
29 ֿ Estimating occurrence of ADR genotypes in UK Biobank: obtaining prescription counts  TopicSem

2020-05:
07 ֿ Synthetic association study for 6-mercaptopurine intolerance  TopicSem
11 ֿ Immune response in Parkinsons disease driven by HLA display of -synuclein peptides  BioEMR
11 ֿ Immune response in Parkinsons disease driven by HLA display of -synuclein peptides  BioEMR
11 ֿ Contribution of genetic variation in drug-drug-gene-interactions  SysBiol
11 ֿ Contribution of genetic variation in drug–drug–gene interactions  SysBiol
16 ֿ Pharmacogenomic-Based Decision-Support to Predict Adherence to Medications     J.Club

2020-04:
06 ֿ Synthetic association analysis for tacrolimus response  TopicSem
06 ֿ SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions  BioEMR

2020-03:
09 ֿ Review of PGx-Passport: a DPWG-based preemptive pharmacogenetic testing panel  BioEMR
09 ֿ The design and implementation strategy of European pharmacogenomics through the U-PGx consortium  SysBiol
09 ֿ The design and implementation strategy of European pharmacogenomics through the U-PGx consortium  SysBiol
12 ֿ Gene-wise analysis of Parkinsons disease candidate SAGs  TopicSem
21 ֿ Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands     J.Club

2020-02:
03 ֿ Detection of variants contributing to synthetic association in Parkinsons disease  TopicSem

2020-01:
06 ֿ Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention (PCI)  BioEMR
18 ֿ Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults     J.Club

2019-12:
02 ֿ Pathway-based analysis for cSAGs of Parkinsons disease  BioEMR
23 ֿ Evaluation of cSAGs in Parkinsons disease based on association analysis   TopicSem
23 ֿ Examination of Parkinsons disease cSAG deleteriousness using GVB score and pathway analysis  SysBiol

2019-11:
21 ֿ Evaluation of candidate SAGs contributing to Parkinsons disease  TopicSem

2019-10:
17 ֿ Evaluation of candidate genes contributing to synthetic association  TopicSem
21 ֿ Evaluation of systematic synthetic association-contributing variant detection  Seminar
26 ֿ Analyzing the Clinical Actionability of Germline Pharmacogenomic Findings in Oncology     J.Club
28 ֿ Examination of variants potentially contributing to synthetic association in Parkinson's disease  BioEMR
28 ֿ Evaluation of candidate SAGs using tacrolimus sample WXS data  SysBiol

2019-09:
05 ֿ Candidate SAG extraction and evaluation using tacrolimus sample data  TopicSem
09 ֿ Candidate SAG evaluation using tacrolimus sample data  SysBiol
16 ֿ Examination of Stargazer through application to 1000 Genomes Project data  BioEMR

2019-08:
05 ֿ Utility of extended Stargazer for calling star alleles with WGS data  BioEMR
24 ֿ Characterizing pharmacogenomic-guided medication use with a clinical data repository     J.Club

2019-07:
01 ֿ A clinical trial testing the effects of CYP2D6-guided versus usual opioid prescribing on pain control  BioEMR
15 ֿ ADR related synthetic association study: data processing flow and statistics  SysBiol
22 ֿ Refining method of candidate SAG extraction   TopicSem

2019-06:
08 ֿ Network, transcriptomic and genomic features differentiate genes relevant for drug response     J.Club
17 ֿ Candidate SAG characteristic examination based on drug-gene interaction status  TopicSem

2019-05:
02 ֿ Synthetic association analysis of PGx variants extracted from GWAS  TopicSem
27 ֿ Linkage disequilibrium between PGx GWAS and candidate SAG variants  BioEMR
27 ֿ Candidate SAG interpretation based on inter-ethnic variability  SysBiol

2019-04:
01 ֿ Star allele determination overview and exploration of methods  TopicSem
08 ֿ A disease-drug database to support drug prescribing based on patient pharmacogenomics test results  SysBiol
13 ֿ Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing     J.Club
15 ֿ CYP2D6 star allele calling with Stargazer  BioEMR

2019-02:
02 ֿ Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients     J.Club
11 ֿ Progress in troubleshooting of LSPE study error  BioEMR
14 ֿ Synthetic association analysis with significant variants from PGx GWAS studies  TopicSem
14 ֿ Evaluation of synthetic association detection using gene deleteriousness scores in hearing loss case  SysBiol

2019-01:
10 ֿ Evaluation of gene deleteriousness scores in the confirmation synthetic association signals  TopicSem

2018-12:
06 ֿ Evaluation of candidate SAGs with focus on drug-gene interactions  TopicSem
13 ֿ ITPA gene variants protecting against anemia as a case of synthetic association  SysBiol
26 ֿ Variants contributing to adverse drug reactions through synthetic association  Seminar
31 ֿ Addressing issues of applying the Large-Scale Population-Level Evidence Generation study in K-CDM  BioEMR

2018-11:
01 ֿ Progress in validation of synthetic association between candidate SAG and PGx variants  TopicSem
17 ֿ Whole genome sequencing identifies high-impact variants in well-known pharmacogenomic genes     J.Club
19 ֿ Application of the Large-Scale Population-Level Evidence Generation R package in K-CDM  BioEMR

2018-10:
08 ֿ Evaluation of the candidate genes in synthetic association to tacrolimus ADR biomarkers  TopicSem
15 ֿ Evaluating relation between isoniazid and liver injury using KCDM  BioEMR
15 ֿ Evaluating association between isoniazid and liver injury using KCDM  BioEMR
18 ֿ Characteristics of candidate SAGs with regard to ethnicity  SysBiol

2018-09:
29 ֿ Quantifying the impact of rare and ultra-rare coding variation across the phenotypic spectrum     J.Club

2018-08:
09 ֿ Using TCGA for validation of synthetic association   SysBiol
09 ֿ Progress in evaluating relation between isoniazid and liver injury  BioEMR
20 ֿ Trial of validating genes with variants in synthetic association to PGx biomarkers using TCGA  TopicSem

2018-07:
05 ֿ Evaluation of ADR signal detected using K-CDM and KAERS reports  BioEMR
05 ֿ Evaluation of ADR signal detected using K-CDM and KAERS reports  BioEMR
14 ֿ Impact of germline and somatic missense variations on drug binding sites     J.Club
23 ֿ Statistics and interpretation of genes with variants in synthetic association to PGx variants  TopicSem

2018-06:
21 ֿ Interpretation of genes with variants in synthetic association to ADR biomarkers  TopicSem
21 ֿ Signatures and examples of synthetic association  SysBiol
21 ֿ Signatures and examples of synthetic association  SysBiol

2018-05:
24 ֿ Use of K-CDM and KAERS report for proactive surveillance of ADRs  BioEMR
26 ֿ Patient-Centered Precision Health In A Learning Health Care System: Geisingers Genomic Medicine Experience     J.Club
28 ֿ Characteristics of genes synthetically associated to ADR biomarkers   TopicSem

2018-04:
12 ֿ Generating evidence for the comparative effectiveness of treatment pairs using the LargeScalePopEst R package  BioEMR
12 ֿ Generating evidence for the comparative effectiveness of treatment pairs using the LargeScalePopEst R package  BioEMR
12 ֿ Generating evidence for the comparative effectiveness of treatment pairs using the LargeScalePopEst R package  BioEMR
16 ֿ Extracting genes with variants in synthetic association to PGx variants  TopicSem
26 ֿ Evaluation of extracting genes with variants in synthetic association to ADR biomarkers  SysBiol

2018-03:
05 ֿ Interpretation of PGx variant candidate SAGs  TopicSem

2018-02:
14 ֿ Linking K-CDM to KAERS for active ADE signal detection  BioEMR
24 ֿ Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention     J.Club
28 ֿ Interpretation of genes in synthetic association to PGx variants: a case study  SysBiol

2018-01:
02 ֿ Gene set annotation of genes synthetically associated with PGx variants in GWAS  TopicSem
11 ֿ Pathway annotation of genes synthetically associated to GWAS PGx variants  SysBiol
29 ֿ Interpretation of the relation between SAGs of PGx variants and ADEs  TopicSem
31 ֿ Pathway enrichment analysis for FDA and GWAS PGx variants  SysBiol

2017-12:
14 ֿ Gene set annotation for genes synthetically associated with PGx variants  SysBiol
16 ֿ Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing     J.Club

2017-11:
16 ֿ Using standard queries to analyze ADR risks across multiple institutions  SysBiol
16 ֿ Using standard queries to analyze ADR risks across multiple institutions  SysBiol
27 ֿ Finding genes synthetically associated with PGx variants of GWAS  TopicSem

2017-10:
14 ֿ Multidisciplinary model to implement pharmacogenomics at the point of care     J.Club
16 ֿ Variant level analysis of genes in synthetic association to PGx variants: case for rs4646244 TA, AA  SysBiol
16 ֿ Variant level analysis of genes in synthetic association to PGx variants: case for rs4646244 TA, AA  SysBiol
25 ֿ Finding genes synthetically associated to PGx variants in GWAS  TopicSem

2017-09:
11 ֿ Extracting variants associated to drug response from the NHGRI GWAS Catalog  SysBiol
13 ֿ Analysis of synthetically associated genes to PGx variants  TopicSem

2017-08:
07 ֿ Extraction and analysis of genes synthetically associated with PGx alleles  TopicSem
07 ֿ Results of predominant and synthetically associated genes to PGx alleles  SysBiol
07 ֿ synthetic association study  SysBiol
07 ֿ synthetic association study  SysBiol
07 ֿ synthetic association study  SysBiol
07 ֿ synthetic association study  SysBiol

2017-07:
03 ֿ Updated statistics for determining ADR risk according to PGx variant status using synthetic association  SysBiol
05 ֿ Variant level analysis of genes synthetically associated with PGx alleles  TopicSem
22 ֿ Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cas     J.Club

2017-06:
05 ֿ ADR risk determination according to PGx variant statususing synthetic association  TopicSem

2017-05:
27 ֿ Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration-experience from a pediatric tertiary care facility     J.Club
29 ֿ ADR risk according to 8 PGx variant statuses using synthetic association  SysBiol

2017-04:
24 ֿ Statistics of updated PGx variants for synthetic association analysis  SysBiol
26 ֿ ADR risk determination according to PGx variant status using synthetic association  TopicSem

2017-03:
11 ֿ Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial     J.Club
13 ֿ Visualization of variants grouped by genes in synthetic association with PGx variants  SysBiol
22 ֿ ADR risk determination according to PGx variant status using synthetic association  TopicSem

2017-02:
01 ֿ ADR risk determination according to FDA or PREDICT SNP genotype using synthetic association  TopicSem

2017-01:
23 ֿ Chromosomal distribution of variants synthetically associated with pharmacogenomic SNPs  SysBiol

2016-12:
10 ֿ Identification of causal genes for complex traits     J.Club
12 ֿ Determining adverse drug event risk according to FDA SNP genotype  SysBiol
12 ֿ Determining adverse drug event risk according to FDA SNP genotype  SysBiol
12 ֿ Determining adverse drug event risk according to FDA SNP genotype  SysBiol
12 ֿ Determining adverse drug event risk according to FDA SNP genotype using synthetic association  SysBiol
26 ֿ Determining ADR risk according to FDA & PREDICT SNP genotype  TopicSem
30 ֿ Determining ADR risk according to FDA & PREDICT SNP genotypes  Seminar

2016-11:
09 ֿ Gene score distribution of genes including or proximate to pharmacogenomic SNPs  TopicSem

2016-10:
10 ֿ South Korean geriatrics on Beers Criteria medications at risk of adverse drug events  TopicSem
31 ֿ Results of variant-centric approach for MRONJ  SysBiol
31 ֿ Human BioPathway Databases  SysBiol

2016-09:
19 ֿ Risk for ADEs in South Korean geriatrics from Beers Criteria medications  SysBiol
24 ֿ The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy     J.Club

2016-08:
01 ֿ Distribution of F10 mutations in the 1000 Genomes phase 3 population  SysBiol
10 ֿ Finding genomic features that affect drug response  TopicSem

2016-07:
09 ֿ Computational discovery of transcription factors associated with drug response     J.Club
11 ֿ Assessing drug response based on genetic mutation and expression  TopicSem

2016-06:
08 ֿ Mutations that change drug response due to altered gene expression  TopicSem
13 ֿ Detecting candidate variants of MRONJ occurrence  SysBiol

2016-05:
02 ֿ Predicting drugs related to treatment failure based on CNVs  TopicSem

2016-04:
25 ֿ CNV and gene expression profile in 1000 Genomes phase 3 population  SysBiol
25 ֿ CNV and gene expression profile in 1000 Genomes phase 3 population  SysBiol
25 ֿ Association between CNV and gene expression using 1000 Genomes data  SysBiol
25 ֿ Copy number variation and gene expression in 1000 Genomes phase 3 population  SysBiol
25 ֿ Association between CNV and gene expression using 1000 Genomes data  SysBiol

2016-03:
08 ֿ Review of very important pharmacogenes in PharmGKB  SysBiol
23 ֿ Predicting high risk drugs in 1KP based on pharmacogene CNVs  TopicSem

2016-02:
15 ֿ Variant centric analysis for MRONJ  TopicSem
20 ֿ A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program     J.Club

2016-01:
06 ֿ Finding genetic variants associated with increased risk for BRONJ  TopicSem
19 ֿ Model on predicting patients likely to benefit from preemptive genotying  SysBiol

2015-12:
02 ֿ Breakeven analysis of preemptive genotyping  TopicSem
12 ֿ Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians     J.Club
15 ֿ Review of clinical outcomes from pharmacogenotyping  SysBiol
29 ֿ Indications and pharmacologic action of frequently prescribed drugs in US and South Korea  SysBiol

2015-11:
03 ֿ Review of pharmacoeconomic analysis methods  SysBiol
24 ֿ Application of breakeven analysis for preemptive genotyping  SysBiol

2015-10:
13 ֿ Review of pharmacogene-related ADRs in Koreans  SysBiol
26 ֿ Economic evaluation of preemptive genotyping  TopicSem

2015-09:
01 ֿ Distribution of drug usage extent in HIRA 2011 patients  SysBiol
12 ֿ Electronic health record design and implementation for pharmacogenomics: a local perspective     J.Club
16 ֿ Preemptive genotyping to prevent ADEs: figures and tables  TopicSem
22 ֿ Overview of Korea Adverse Event Reporting System  SysBiol

2015-08:
05 ֿ Results for preemptive genotyping to prevent adverse drug events  TopicSem
11 ֿ Trend in predicted number of people with serious AE over year 2011  SysBiol

2015-07:
07 ֿ Refined figures for patient demographics and calculation results of preemptive PG study  SysBiol
11 ֿ Refined figures for patient demographics and calculation results of preemptive PG study  SysBiol
28 ֿ Progress of figures on number of patients predicted to have AEs based on genotype  SysBiol

2015-06:
13 ֿ Adoption of a clinical PGx implementation program during outpatient care--initial results of the University of Chicago 1,200 Patients Project     J.Club
16 ֿ Additional results of preemptive genotyping calculation algorithm using 1KP ancestry  SysBiol
16 ֿ Additional results of preemptive genotyping calculation algorithm using 1KP ancestry  SysBiol
29 ֿ Preemptive genotyping to prevent ADEs: ancestry-weighted calculation results  TopicSem

2015-05:
06 ֿ Calculation workflow for showing need for preemptive genotyping   SysBiol
26 ֿ Calculation scheme for predicting number of people with adverse events using ancestry-weights  SysBiol
27 ֿ Preemptive genotyping for ADE prevention: ancestry weighted calculation scheme  TopicSem

2015-04:
11 ֿ Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands      J.Club
27 ֿ Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2015-03:
23 ֿ Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2015-02:
02 ֿ Preemptive genotyping for prevention of drug-related adverse events  TopicSem
07 ֿ PG4KDS: A Model for the Clinical Implementation of Pre-Emptive Pharmacogenetics     J.Club
17 ֿ Statistics of processed year 2011 HIRA data  SysBiol

2015-01:
05 ֿ AMIA: Developing a Formal Representation for Medication Appropriateness Criteria   TopicSem
06 ֿ Comparison of statistics for inpatient and outpatient prescriptions of year 2011  SysBiol
26 ֿ SG05 rarepedia     Seminar
27 ֿ Overview of HIRA 2011 statistics  SysBiol

2014-12:
13 ֿ Development and use of active clinical decision support for preemptive pharmacogenomics     J.Club
16 ֿ Statistics of year 2011 HIRA data and PREDICT study data  SysBiol
16 ֿ Statistics of year 2011 HIRA data and PREDICT study data  SysBiol
29 ֿ Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2014-11:
24 ֿ Preemptive genotyping for prevention of drug-related adverse events  TopicSem
24 ֿ SG05 Interpretation  Seminar
25 ֿ Calculating number of preventable adverse events with HIRA data using PREDICT algorithm  SysBiol

2014-10:
20 ֿ Preemptive genotyping for prevention of drug-related adverse events  TopicSem
22 ֿ Statistics of year 2011 HIRA patient and drug data  SysBiol

2014-09:
01 ֿ IODINE: prescriber & patient-accessible health information platform  TopicSem
20 ֿ Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems     J.Club
24 ֿ Calculation of number of potential adverse events prevented from preemptive genotyping-meta analysis process  SysBiol
24 ֿ Calculation of number of potential adverse events prevented from preemptive genotyping-meta analysis process  SysBiol

2014-08:
16 ֿ Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol     J.Club
19 ֿ Examination of number of preventable adverse events using PREDICT algorithm and HIRA drug claims data  SysBiol
26 ֿ Review of Iodine website  SysBiol
31 ֿ Review of the roles and mechanisms of proteins encoded by pharmacogenes  SysBiol

2014-07:
01 ֿ Examination of number of patients prescribed drugs with clinically severe AEs modulated by variant alleles  SysBiol
22 ֿ Examination of the frequency of pharmacogenetic medication prescribing in Korea  SysBiol
22 ֿ Examination of the frequency of pharmacogenetic medication prescribing in Korea  SysBiol
26 ֿ Computational Drug Repositioning: From Data to Therapeutics     J.Club
28 ֿ Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2014-06:
10 ֿ Review of FDA-approved drugs with pharmacogenomic information in their labeling  SysBiol
30 ֿ Preemptive genotyping for prevention of drug-related adverse events  TopicSem

2014-05:
17 ֿ Optimizing Drug Outcomes through Pharmacogenetics: a Case for Preemptive genotyping     J.Club
20 ֿ Examination of data in Korea Health Insurance Review & Assessment Service  SysBiol
28 ֿ Identifying the need of prospective genotyping  TopicSem

2014-04:
08 ֿ Review of Cancer Genome Project database  SysBiol
08 ֿ Review of Cancer Genome Project database   SysBiol
08 ֿ Review of Cancer Genome Project database   SysBiol
08 ֿ Review of Cancer Genome Project database   SysBiol
28 ֿ Finding genomic factors that regulate drug efficacy  TopicSem

2014-03:
18 ֿ Role and mechanisms of drug targets, enzymes, transporters, and carriers  SysBiol
18 ֿ Role and mechanisms of drug targets, enzymes, transporters, and carriers  SysBiol
29 ֿ DGIdb: mining the druggable genome     J.Club

powered by SNUBI